Blood Pressure Lowering Effect of B-vitamins in Adults With a Genetic Pre-disposition to Elevated Blood Pressure.
NCT ID: NCT04278378
Last Updated: 2021-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2564 participants
INTERVENTIONAL
2011-06-28
2019-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Pressure and Central Haemodynamics in Healthy Adults Stratified by MTHFR Genotype
NCT04948086
RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure
NCT02463513
Optimal Nutrition for Prevention of Hypertension in Pregnancy
NCT04723836
Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the MTHFR C677T Genotype
NCT03151096
Effect of Betaine and Folic Acid on Vascular Function in Healthy Humans
NCT00102843
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Riboflavin
1.6 mg riboflavin / day for 24 weeks
Riboflavin
1.6 mg riboflavin / day for 24 weeks
Folic Acid
0.4 mg folic acid/ day for 24 weeks
Folic acid
0.4 mg folic acid / day for 24 weeks
Riboflavin + Folic Acid
1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
Riboflavin
1.6 mg riboflavin / day for 24 weeks
Folic acid
0.4 mg folic acid / day for 24 weeks
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Riboflavin
1.6 mg riboflavin / day for 24 weeks
Folic acid
0.4 mg folic acid / day for 24 weeks
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant or planning to conceive
* Taking medications interfering with folate metabolism
* Renal or gastrointestinal disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Ulster
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Human Intervention Studies Unit, Ulster University
Coleraine, Co.Londonderry, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REC/11/0081
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.